Rabaca, Saturnino J.

HRN: 22-29-77  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/05/2023
CO-AMOXICLAV 625MG (TAB)
11/05/2023
11/11/2023
ORAL
625mg
Bid
PHLEBITIS, CAP
Waiting Final Action 

Indication:  Empiric    Type of Infection:  PneumoniaSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: